-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Malaria [strain 7G8] Vaccine in Malaria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Malaria [strain 7G8] Vaccine in Malaria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Malaria [strain 7G8] Vaccine in Malaria Drug Details: Vaccine candidate...
-
Sector Analysis
NewEgypt Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Egypt Defense Market Report Overview In 2024, Egypt's defense budget is worth $5.2 billion, inclusive of US military aid. The country’s defense budget will grow at a CAGR of more than 3% during 2025-2029. Egypt’s increasing military expenditure is reflected in an ongoing modernization effort to counter terrorism in the Sinai Peninsula, strained relations with Ethiopia, political turmoil following the democratic revolution, and maritime security concerns over the Suez Canal. Furthermore, the country’s strained relations with Ethiopia over the construction...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Measles [strain Edmonstons-Zagreb] + Rubella [strain RA-27]) Vaccine in Measles
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Measles [strain Edmonstons-Zagreb] + Rubella [strain RA-27]) Vaccine in Measles report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Measles [strain Edmonstons-Zagreb] + Rubella...
-
Product Insights
NewLikelihood of Approval Analysis for Staphylococcus aureus Infections
Overview How likely is it that the drugs in Staphylococcus aureus Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Staphylococcus aureus Infections Overview Staphylococcus aureus is a Gram-positive spherically shaped...
-
Product Insights
NewLikelihood of Approval Analysis for Avian Influenza
Overview How likely is it that the drugs in Avian Influenza will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avian Influenza Overview Avian influenza, commonly referred to as bird flu, is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Measles [strain Edmonstons-Zagreb] + Rubella [strain RA-27]) Vaccine in Rubella (German Measles)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Measles [strain Edmonstons-Zagreb] + Rubella [strain RA-27]) Vaccine in Rubella (German Measles) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Measles [strain Edmonstons-Zagreb]...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nipah [strain Bangladesh] Vaccine in Nipah Virus (NiV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nipah [strain Bangladesh] Vaccine in Nipah Virus (NiV) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nipah [strain Bangladesh] Vaccine in Nipah Virus...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SCB-1019 in Respiratory Syncytial Virus (RSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SCB-1019 in Respiratory Syncytial Virus (RSV) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SCB-1019 in Respiratory Syncytial Virus (RSV) Infections Drug Details:...
-
Product Insights
NewNet Present Value Model: Vaxart Inc’s Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Empower your strategies with our Net Present Value Model: Vaxart Inc's Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval Analysis for Influenza A Virus, H1N1 Subtype Infections
Overview How likely is it that the drugs in Influenza A Virus, H1N1 Subtype Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Influenza A Virus, H1N1 Subtype Infections Overview H1N1...